Mgr. Marek Borský

Vzdělání

1997 - Mgr. -  Molekulární biologie, PřF MU Brno

2008 - atestace "Vyšetřovací metody v klinické hematologii"

Pozice

1997 - 2002  Výzkumný ústav zdraví dítěte

2002 - dodnes, JOP s VŠ, Centrum molekulární biologie a genové terapie, IHOK, FN Brno

2011 - dodnes, vedoucí sekce průtokové cytometrie, Centrum molekulární biologie a genové terapie, IHOK, FN Brno

        Členství

Česká společnost pro analytickou cytometrii

Česká hematologická společnost

Vybrané publikace

[1]    J. Zemanova, O. Hylse, J. Collakova, P. Vesely, A. Oltova, M. Borsky, K. Zaprazna, M. Kasparkova, P. Janovska, J. Verner, J. Kohoutek, M. Dzimkova, V. Bryja, Z. Jaskova, Y. Brychtova, K. Paruch, M. Trbusek, J. Zemanova, O. Hylse, J. Collakova, P. Vesely, A. Oltova, M. Borsky, K. Zaprazna, M. Kasparkova, P. Janovska, J. Verner, J. Kohoutek, M. Dzimkova, V. Bryja, Z. Jaskova, Y. Brychtova, K. Paruch, and M. Trbusek, “Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells,” Oncotarget, vol. 5, no. 0, Aug. 2016.

[2]    G. Pavlasova, M. Borsky, V. Seda, K. Cerna, J. Osickova, M. Doubek, J. Mayer, R. Calogero, M. Trbusek, S. Pospisilova, M. S. Davids, T. J. Kipps, J. R. Brown, and M. Mraz, “Ibrutinib inhibits CD20 up-regulation on CLL B cells mediated by the CXCR4/SDF-1 axis,” Blood, Aug. 2016.

[3]    B. Kantorova, J. Malcikova, K. Brazdilova, M. Borsky, K. Plevova, J. Smardova, L. Radova, N. Tom, M. Trbusek, E. Diviskova, H. S. Francova, V. Navrkalova, M. Doubek, Y. Brychtova, J. Mayer, and S. Pospisilova, “Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients,” Br. J. Haematol., Jul. 2016.

[4]    P. Janovska, L. Poppova, K. Plevova, H. Plesingerova, M. Behal, M. Kaucka, P. Ovesna, M. Hlozkova, M. Borsky, O. Stehlikova, Y. Brychtova, M. Doubek, M. Machalova, S. Baskar, A. Kozubik, S. Pospisilova, S. Pavlova, and V. Bryja, “Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia,” Clinical Cancer Research, vol. 22, no. 2, pp. 459–469, Jan. 2016.

[5]    M. Culen, M. Borsky, V. Nemethova, F. Razga, J. Smejkal, T. Jurcek, D. Dvorakova, D. Zackova, B. Weinbergerova, L. Semerad, I. Sadovnik, G. Eisenwort, H. Herrmann, P. Valent, J. Mayer, Z. Racil, M. Culen, M. Borsky, V. Nemethova, F. Razga, J. Smejkal, T. Jurcek, D. Dvorakova, D. Zackova, B. Weinbergerova, L. Semerad, I. Sadovnik, G. Eisenwort, H. Herrmann, P. Valent, J. Mayer, and Z. Racil, “Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects,” Oncotarget, vol. 7, no. 22, pp. 33016–33024, Apr. 2016.

[6]    P. Janovska, L. Poppova, K. Plevova, H. Plesingerova, M. Behal, M. Kaucka, P. Ovesna, M. Hlozkova, M. Borsky, O. Stehlikova, Y. Brychtova, M. Doubek, M. Machalova, S. Baskar, A. Kozubik, S. Pospisilova, S. Pavlova, and V. Bryja, “Autocrine signaling by Wnt-5a deregulates chemotaxis of leukemic cells and predicts clinical outcome in chronic lymphocytic leukemia,” Clinical Cancer Research: An Official Journal Of The American Association For Cancer Research, Aug. 2015.

[7]    O. Stehlíková, J. Chovancová, B. Tichý, M. Krejčí, Y. Brychtová, A. Panovská, H. Francová Skuhrová, K. Burčková, M. Borský, T. Loja, J. Mayer, Š. Pospíšilová, and M. Doubek, “Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice,” International Journal of Laboratory Hematology, vol. 36, no. 2, p. 165, Apr. 2014.

[8]    L. Sebejova, M. Borsky, Z. Jaskova, D. Potesil, V. Navrkalova, J. Malcikova, M. Sramek, M. Doubek, T. Loja, S. Pospisilova, J. Mayer, and M. Trbusek, “Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab,” Experimental Hematology, vol. 42, no. 10, p. 867–74.e1, Oct. 2014.

[9]    D. Potěšil, S. Stejskal, M. Borský, P. Šimara, M. Havelková, F. Rázga, I. Koutná, D. Dvořáková, J. Mayer, Z. Ráčil, and Z. Zdráhal, “Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry,” Analytical Letters, vol. 47, no. 6, pp. 944–957, Apr. 2014.

[10]  M. ( 1 ) Musilova, F. ( 1 Razga 2 ), T. ( 1 ) Jurcek, I. ( 1 ) Jeziskova, M. ( 1 ) Borsky, V. ( 1 Nemethova 2 ), D. ( 1 ) Zackova, M. ( 1 Culen 3 ), D. ( 1 Dvorakova 3 ), J. ( 1 Mayer 3 ), and Z. ( 1 Racil 3 ), “BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing,” American Journal of Hematology, vol. 89, no. 10, pp. 1016–1017, 01 2014.

[11]  T. ( 1 ) Jurcek, F. ( 1 Razga 2 ), P. ( 1 ) Mazancova, D. ( 1 Dvorakova 3 ), M. ( 1 ) Borsky, D. ( 1 ) Zackova, B. ( 1 ) Dobesova, L. ( 1 ) Semerad, J. ( 1 Mayer 3 ), Z. ( 1 Racil 3 ), and M. ( 3 ) Musilova, “Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34 + cells of patients with de novo chronic myeloid leukemia,” Leukemia and Lymphoma, vol. 55, no. 8, pp. 1915–1917, 01 2014.

[12]  M. Mraz, K. Kozubik, K. Plevova, K. Musilova, B. Tichy, M. Borsky, P. Kuglik, M. Doubek, Y. Brychtova, J. Mayer, and S. Pospisilova, “The origin of deletion 22q11 in chronic lymphocytic leukemia is related to the rearrangement of immunoglobulin lambda light chain locus,” LEUKEMIA RESEARCH, vol. 37, no. 7, pp. 802–808, Jul. 2013.

[13]  D. Dvorakova, Z. Racil, M. Borsky, B. Robesova, I. Jeziskova, F. Razga, M. Lengerova, and J. Mayer, “Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations,” LEUKEMIA & LYMPHOMA, vol. 54, no. 5, pp. 1056–1060, May 2013.

[14]  F. Razga, T. Jurcek, I. Jeziskova, D. Zackova, D. Dvorakova, M. Borsky, J. Mayer, and Z. Racil, “Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood,” Molecular Diagnosis & Therapy, vol. 16, no. 3, pp. 163–166, Jun. 2012.

[15] M. Mraz, D. Dolezalova, K. Plevova, K. Kozubik, V. Mayerova, K. Cerna, K. Musilova, B. Tichy, S. Pavlova, M. Borsky, J. Verner, M. Doubek, Y. Brychtova, M. Trbusek, A. Hampl, J. Mayer, and S. Pospisilova, “MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia,” BLOOD, vol. 119, no. 9, pp. 2110–2113, Mar. 2012.

[16]  O. Horky, J. Mayer, L. Kablaskova, F. Razga, M. Krejci, J. Kissova, M. Borsky, I. Jeziskova, and D. Dvorakova, “Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse,” INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, vol. 33, no. 1, pp. 57–66, Feb. 2011.

  


Ke stažení


zde může být Vaše reklama logo Zbrojovky Brno logo Lékaři bez hranic
Kalendář akcí
říjen
Po Út St Čt So Ne
1
2345678
9101112131415
16171819202122
23 242526 272829
3031
2017
Anketa
Setkali jste se ve FN Brno s korupčním jednáním?



CZ ENG DE

změnit velikost písma

Jihlavská 20, 625 00 Brno
+420 532 23 1111

NIAHOSM ISO 9001:2008 ISO 14001:2001